{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:13:40Z","timestamp":1792700020750,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T00:00:00Z","timestamp":1697846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jaad.2023.10.020","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T12:09:00Z","timestamp":1697458140000},"page":"485-493","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial"],"prefix":"10.1016","volume":"90","author":[{"given":"Joseph F.","family":"Merola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence Charles","family":"Parish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyn","family":"Guenther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Lynde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Lacour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Staubach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Paris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hernan","family":"Picard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Deignan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shauna","family":"Jardon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindy","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim A.","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jaad.2023.10.020_bib1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/000155599750009870","article-title":"Validity study for the stigmatization experience in atopic dermatitis and psoriatic patients","volume":"79","author":"Schmid-Ott","year":"1999","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"10.1016\/j.jaad.2023.10.020_bib2","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.jaad.2015.02.1127","article-title":"Genital psoriasis is associated with significant impairment in quality of life and sexual functioning","volume":"72","author":"Ryan","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2023.10.020_bib3","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s13555-017-0204-3","article-title":"Patients' perspectives on the impact of genital psoriasis: a qualitative study","volume":"7","author":"Cather","year":"2017","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"10.1016\/j.jaad.2023.10.020_bib4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000338858","article-title":"Patients' experience of psoriasis in the genital area","volume":"224","author":"Meeuwis","year":"2012","journal-title":"Dermatology"},{"issue":"1","key":"10.1016\/j.jaad.2023.10.020_bib5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2340\/00015555-0988","article-title":"Genital psoriasis: a systematic literature review on this hidden skin disease","volume":"91","author":"Meeuwis","year":"2011","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2023.10.020_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","article-title":"Definition of treatment goals for moderate to severe psoriasis: a European consensus","volume":"303","author":"Mrowietz","year":"2011","journal-title":"Arch Dermatol Res"},{"issue":"6","key":"10.1016\/j.jaad.2023.10.020_bib7","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/bjd.21827","article-title":"Using the upgrade criteria of the European psoriasis consensus is best practice care according to the people-centred healthcare concept of the World Health Organization","volume":"187","author":"Mrowietz","year":"2022","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2023.10.020_bib8","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.16736","article-title":"Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis","volume":"179","author":"Ryan","year":"2018","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2023.10.020_bib9","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.jsxm.2018.09.004","article-title":"Ixekizumab improved patient-reported genital psoriasis symptoms and impact of symptoms on sexual activity vs placebo in a randomized, double-blind study","volume":"15","author":"Yosipovitch","year":"2018","journal-title":"J Sex Med"},{"issue":"1","key":"10.1016\/j.jaad.2023.10.020_bib10","doi-asserted-by":"crossref","first-page":"adv00006","DOI":"10.2340\/00015555-3353","article-title":"Ixekizumab results in persistent clinical improvement in moderate-to-severe genital psoriasis during a 52 week, randomized, placebo-controlled, phase 3 clinical trial","volume":"100","author":"Guenther","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2023.10.020_bib11","series-title":"Taltz [package insert]","year":"2021"},{"key":"10.1016\/j.jaad.2023.10.020_bib12","series-title":"Otezla [package insert]","year":"2023"},{"issue":"1","key":"10.1016\/j.jaad.2023.10.020_bib13","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM 1])","volume":"73","author":"Papp","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2023.10.020_bib14","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bjd.14164","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2)","volume":"173","author":"Paul","year":"2015","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2023.10.020_bib15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jaad.2021.07.040","article-title":"Efficacy and safety of apremilast in patients with mild to moderate plaque psoriasis: results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial","volume":"86","author":"Stein Gold","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2023.10.020_bib16","first-page":"793","article-title":"The static Physician's Global Assessment of Genitalia: a clinical outcome measure for the severity of genital psoriasis","volume":"16","author":"Merola","year":"2017","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2023.10.020_bib17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s13555-017-0213-2","article-title":"The development of a patient-reported outcome measure for assessment of genital psoriasis symptoms: the Genital Psoriasis Symptoms Scale (GPSS)","volume":"8","author":"Gottlieb","year":"2018","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"10.1016\/j.jaad.2023.10.020_bib18","first-page":"997","article-title":"The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results","volume":"159","author":"Basra","year":"2008","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2023.10.020_bib19","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jaad.2017.01.052","article-title":"Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for \u2265156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)","volume":"77","author":"Crowley","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2023.10.020_bib20","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jaad.2020.01.072","article-title":"Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study","volume":"83","author":"Van Voorhees","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2023.10.020_bib21","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s13555-022-00747-5","article-title":"Efficacy and safety of apremilast in the treatment of patients with mild-to-moderate psoriasis in Japan: results from PROMINENT, a phase 3b, open-label, single-arm study","volume":"12","author":"Okubo","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"10.1016\/j.jaad.2023.10.020_bib22","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s13555-021-00628-3","article-title":"Real-world experience of patient-relevant benefits and treatment satisfaction with apremilast in patients with psoriasis: an analysis of the APPRECIATE study","volume":"12","author":"Klein","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"10.1016\/j.jaad.2023.10.020_bib23","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/jdv.18689","article-title":"Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas, and impaired quality of life: results from the EMBRACE randomized trial","volume":"37","author":"Mrowietz","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2023.10.020_bib24","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/14712598.2021.1843629","article-title":"A randomized controlled ixekizumab vs secukinumab trial to study the impact on sexual activity in adult patients with genital psoriasis","volume":"21","author":"AlMutairi","year":"2021","journal-title":"Expert Opin Biol Ther"},{"issue":"12","key":"10.1016\/j.jaad.2023.10.020_bib25","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1111\/1346-8138.16128","article-title":"Real-world effectiveness of guselkumab in patients with psoriasis: health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial","volume":"48","author":"Gerdes","year":"2021","journal-title":"J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.10.020_bib26","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1111\/jdv.17880","article-title":"A head-to-head comparison of risankizumab and ixekizumab for genital psoriasis: a real-life, 24-week, prospective study","volume":"36","author":"Sotiriou","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"10.1016\/j.jaad.2023.10.020_bib27","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jama.2022.15632","article-title":"Effect of roflumilast cream vs vehicle cream on chronic plaque psoriasis: the DERMIS-1 and DERMIS-2 randomized clinical trials","volume":"328","author":"Lebwohl","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2023.10.020_bib28","series-title":"Zoryve [package insert]","year":"2022"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223030220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223030220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:30:37Z","timestamp":1759275037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962223030220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0190962223030220"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2023.10.020","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2023.10.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}